DOYLESTOWN, Pa., Nov. 16, 2016 /PRNewswire/ -- Atrin Pharmaceuticals, Inc. today announced the election of Jeffrey M. Dayno, M.D., chief medical officer of Egalet Corporation, to the Atrin board of directors.
" Jeffrey Dayno joins the Atrin board with an 18 years of senior track record of senior pharmaceutical industry experience at both global and emerging biopharmaceutical companies in the realm of medical affairs," said Oren Gilad, Ph.D., Atrin Pharmaceuticals President and Chief Executive Officer. "He brings to our board a keen perspective on all aspects of pharmaceutical medicine, clinical development strategy and trial design, and drug regulatory affairs that will serve our company well as we prepare to advance our novel ATR inhibitors into clinical development. I am very pleased to welcome Jeff to the Atrin board of directors." Prior to joining Egalet, a specialty medical pharmaceutical company focused on innovative treatments for pain, in July 2014, Dr. Dayno was vice president, global medical affairs at ViroPharma, Inc., from August 2011 to May 2014. Prior to joining ViroPharma, Dr. Dayno was the chief medical officer at Labopharm, Inc., a drug delivery technology company based in Montreal, Canada, where he first started working in the field of abuse-deterrent opioid product development. Before Labopharm, he was vice president of medical affairs at Cephalon, Inc., from 2005 to 2010. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division. Before moving into leadership roles in the pharmaceutical and biotechnology industry, he spent 10 years in academic and clinical medicine, involved in patient care, teaching, and clinical research. Dr. Dayno earned his medical degree from Temple University School of Medicine.